Brain Navi NaoTrac, the Brain Surgical Navigation Robot, Received European CE Mark Approval in 2021
PR93252
ZHUBEI CITY, Taiwan, Nov. 23, 2021 /PRNewswire=KYODO JBN/ --
Brain Navi Biotechnology, a Taiwan-based startup specializing in innovative
navigation robots, received CE mark approval for brain surgery procedures in Q1
2021 for its NaoTrac, a robotic-assisted surgical robot. As the next step Brain
Navi Biotechnology is planned to be submitted for FDA clearance.
"Long surgery times, high concentration, and precision requires a lot of
physical endurance for neurosurgeons in every procedure. This can in turn
affect the surgery's performance," said Jerry Chen, M.D., the CEO of Brain Navi
Biotechnology. "Utilizing NaoTrac to navigate in the cranial not only reduces
anesthesia time, but also improves the patient's well-being by means of less
invasive interventions."
The NaoTrac is equipped with a high-precision navigation system; the patient
registration is performed with a non-contact machine vision process. Surgical
instruments are recognized in seconds with its patented registration algorithm.
Surgeons can choose the surgery pathway with a 3D vision for precise anatomical
location during the pre-operating planning preparation and monitor the robot
during the entire procedure. The unique navigation procedure allows the surgeon
to plan and let Surgical Navigation act as an assistant.
"Robotics and artificial intelligence are the future of healthcare, with
remarkable potential to not only advance patient care, but increase access to
these benefits. Its essential is to increase the degree of accuracy of the
surgery," said Shinn-Zong Lin, M.D. PhD., Superintendent of Hualien Tzu-Chi
Medical Center. Dr. Lin is also an honored fellow of AAAS (American Association
for the Advancement of Science). Dr. Lin also mentioned that "The technology
used by Surgical Navigation Robot can be used in various medical fields, such
as immunotherapy, cell transplant, microchip implantation, etc., where a high
degree of accuracy is required. Therefore, Surgical Navigation Robot not only
has the ability to execute EVD or tumor resection, but it also has the
potential to collaborate within these fields."
All this robotic technology is based on a SMART (Surface Mapping
Auto-Registration Technology) platform, and is patented by Brain Navi
Biotechnology. It merges machine vision, robotic technology, and algorithms to
achieve "real-time imaging", "precise surgery" and "minimally invasive
outcomes" during surgery. The SMART platform is a highly-extensible technology,
besides neurosurgery, Brain Navi Biotechnology has an Industry-Academia
Cooperation cooperating with Chenggong University of Taiwan to develop a
project for liver ablation navigation. The SMART platform is heading to the
application of the world's top 10 cancer early treatments as the research and
development direction.
Brain Navi Biotechnology is currently searching for strategic partners and
early adopters. Brain Navi Biotechnology will hold a LIVE broadcast to share
THE FUTURE OF ROBOTIC SURGERIES during the 2021 Healthcare EXPO in Taiwan on
December 2nd to 5th, 2021. For more information, visit
https://brainnavi.com/product/naotrac/
SOURCE: Brain Navi Biotechnology Co., Ltd.
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=408541
Caption: Brain Navi NaoTrac, the Brain Surgical Navigation Robot Human trials
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。